跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NULOJIX belatacept (rch) 250mg powder for IV infusion vial - TGA Drug Approval Details
Approvals
/
TGA
/
NULOJIX belatacept (rch) 250mg powder for IV infusion vial
Approved
STANDARD
NULOJIX belatacept (rch) 250mg powder for IV infusion vial
Bristol-Myers Squibb Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
Dec 9, 2025
Approval ID
2838f207143f1306
Company
Bristol-Myers Squibb Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
2838f207143f1306
Product Name
NULOJIX belatacept (rch) 250mg powder for IV infusion vial
Artg Id
179687
Artg Name
NULOJIX belatacept (rch) 250mg powder for IV infusion vial
Sponsor
Bristol-Myers Squibb Australia Pty Ltd
Company Detail Path
/organization/bristol-myers-squibb-australia-pty-ltd
Artg Date
2012-03-15
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
Dec 9, 2025
Approval ID
2838f207143f1306
Type
Standard
Back to TGA Approvals
